BACKGROUND AND OBJECTIVE: Fluorescence-guided imaging to assist in identification of malignant margins has the potential to dramatically improve oncologic surgery. However, a standardized method for quantitative assessment of disease-specific fluorescence has not been investigated. Introduced here is a ratiometric threshold derived from mean fluorescent tissue intensity that can be used to semi-quantitatively delineate tumor from normal tissue. METHODS: Open-field and a closed-field imaging devices were used to quantify fluorescence in punch biopsy tissues sampled from primary tumors collected during a phase 1 trial evaluating the safety of cetuximab-IRDye800 in patients (n = 11) undergoing surgical intervention for head and neck cancer. Fluorescence ratios were calculated using mean fluorescence intensity (MFI) from punch biopsy normalized by MFI of patient-matched tissues. Ratios were compared to pathological assessment and a ratiometric threshold was established to predict presence of cancer. RESULTS: During open-field imaging using an intraoperative device, the threshold for muscle normalized tumor fluorescence was found to be 2.7, which produced a sensitivity of 90.5% and specificity of 78.6% for delineating disease tissue. The skin-normalized threshold generated greater sensitivity (92.9%) and specificity (81.0%). CONCLUSION: Successful implementation of a semi-quantitative threshold can provide a scientific methodology for delineating disease from normal tissue during fluorescence-guided resection of cancer.
BACKGROUND AND OBJECTIVE: Fluorescence-guided imaging to assist in identification of malignant margins has the potential to dramatically improve oncologic surgery. However, a standardized method for quantitative assessment of disease-specific fluorescence has not been investigated. Introduced here is a ratiometric threshold derived from mean fluorescent tissue intensity that can be used to semi-quantitatively delineate tumor from normal tissue. METHODS: Open-field and a closed-field imaging devices were used to quantify fluorescence in punch biopsy tissues sampled from primary tumors collected during a phase 1 trial evaluating the safety of cetuximab-IRDye800 in patients (n = 11) undergoing surgical intervention for head and neck cancer. Fluorescence ratios were calculated using mean fluorescence intensity (MFI) from punch biopsy normalized by MFI of patient-matched tissues. Ratios were compared to pathological assessment and a ratiometric threshold was established to predict presence of cancer. RESULTS: During open-field imaging using an intraoperative device, the threshold for muscle normalized tumor fluorescence was found to be 2.7, which produced a sensitivity of 90.5% and specificity of 78.6% for delineating disease tissue. The skin-normalized threshold generated greater sensitivity (92.9%) and specificity (81.0%). CONCLUSION: Successful implementation of a semi-quantitative threshold can provide a scientific methodology for delineating disease from normal tissue during fluorescence-guided resection of cancer.
Authors: T J A Snoeks; P B A A van Driel; S Keereweer; S Aime; K M Brindle; G M van Dam; C W G M Löwik; V Ntziachristos; A L Vahrmeijer Journal: Mol Imaging Biol Date: 2014-04 Impact factor: 3.488
Authors: Q R J G Tummers; F P R Verbeek; B E Schaafsma; M C Boonstra; J R van der Vorst; G-J Liefers; C J H van de Velde; J V Frangioni; A L Vahrmeijer Journal: Eur J Surg Oncol Date: 2014-02-22 Impact factor: 4.424
Authors: Gooitzen M van Dam; George Themelis; Lucia M A Crane; Niels J Harlaar; Rick G Pleijhuis; Wendy Kelder; Athanasios Sarantopoulos; Johannes S de Jong; Henriette J G Arts; Ate G J van der Zee; Joost Bart; Philip S Low; Vasilis Ntziachristos Journal: Nat Med Date: 2011-09-18 Impact factor: 53.440
Authors: Joost R van der Vorst; Merlijn Hutteman; Katja N Gaarenstroom; Alexander A W Peters; J Sven D Mieog; Boudewijn E Schaafsma; Peter J K Kuppen; John V Frangioni; Cornelis J H van de Velde; Alexander L Vahrmeijer Journal: Int J Gynecol Cancer Date: 2011-11 Impact factor: 3.437
Authors: Christoph Adam; Georg Salomon; Sebastian Walther; Dirk Zaak; Wael Khoder; Armin Becker; Oliver Reich; Andreas Blana; Roman Ganzer; Stefan Denzinger; Gralf Popken; Ronald Sroka; Ruth Knüchel-Clarke; Jens Köllermann; Guido Sauter; Arndt Hartmann; Simone Bertz; Markus Graefen; Hartwig Huland; Wolf Wieland; Christian G Stief Journal: Eur Urol Date: 2009-03-03 Impact factor: 20.096
Authors: John P Gleysteen; J Robert Newman; David Chhieng; Andra Frost; Kurt R Zinn; Eben L Rosenthal Journal: Head Neck Date: 2008-06 Impact factor: 3.147
Authors: Susan L Troyan; Vida Kianzad; Summer L Gibbs-Strauss; Sylvain Gioux; Aya Matsui; Rafiou Oketokoun; Long Ngo; Ali Khamene; Fred Azar; John V Frangioni Journal: Ann Surg Oncol Date: 2009-07-07 Impact factor: 5.344
Authors: Eben L Rosenthal; Lindsay S Moore; Kiranya Tipirneni; Esther de Boer; Todd M Stevens; Yolanda E Hartman; William R Carroll; Kurt R Zinn; Jason M Warram Journal: Clin Cancer Res Date: 2017-04-26 Impact factor: 12.531
Authors: Baowei Fei; Martin T Halicek; Xu Wang; Hongzheng Zhang; James V Little; Kelly R Magliocca; Mihir Patel; Christopher C Griffith; Mark W El-Deiry; Amy Y Chen Journal: Conf Proc IEEE Eng Med Biol Soc Date: 2017-07
Authors: Baowei Fei; Guolan Lu; Xu Wang; Hongzheng Zhang; James V Little; Kelly R Magliocca; Amy Y Chen Journal: Proc SPIE Int Soc Opt Eng Date: 2017-02-14
Authors: Baowei Fei; Guolan Lu; Xu Wang; Hongzheng Zhang; James V Little; Mihir R Patel; Christopher C Griffith; Mark W El-Diery; Amy Y Chen Journal: J Biomed Opt Date: 2017-08 Impact factor: 3.170
Authors: Willemieke S Tummers; Arantza Farina-Sarasqueta; Martin C Boonstra; Hendrica A Prevoo; Cornelis F Sier; Jan S Mieog; Johannes Morreau; Casper H van Eijck; Peter J Kuppen; Cornelis J van de Velde; Bert A Bonsing; Alexander L Vahrmeijer; Rutger-Jan Swijnenburg Journal: Oncotarget Date: 2017-05-26